Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue

Mineralocorticoid receptor overactivation-induced remodeling of obese adipose tissue

Obesity is a chronic disease caused by the long-term interaction of multiple environmental factors on a specific genetic background. Among these factors， the overactivation of mineralocorticoid receptors （MR） plays a significant role in adipose tissue remodeling in obesity. In the obese state， the M...

Full description

Saved in:

Bibliographic Details
Main Author:	WEN Runzhi, WANG Li, ZHAO Naiqian
Format:	Article
Language:	zho
Published:	Editorial Office of Journal of New Medicine 2025-06-01
Series:	Xin yixue
Subjects:	obesity\|mineralocorticoid receptor\|mineralocorticoid receptor antagonist
Online Access:	https://www.xinyixue.cn/fileup/0253-9802/PDF/1751417524508-1021187569.pdf
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Obesity, aldosterone excess, and mineralocorticoid receptor activation: Parallel or intersected circumstances?
by: Houry Puzantian, et al.
Published: (2024-12-01)

Paradigm shift on the role of mineralocorticoid receptor antagonists in hypertension therapy
by: S. R. Gilyarevsky, et al.
Published: (2023-10-01)

Investigating the efficacy of mineralocorticoid receptor antagonists for cardiovascular outcomes in different diseases
by: Jiao Wang, et al.
Published: (2025-08-01)

Cardiovascular-Kidney-Metabolic Effects: Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists
by: Biykem Bozkurt, et al.
Published: (2025-07-01)

Mineralocorticoid receptor antagonists reduce inflammatory signaling independent of myofiber mineralocorticoid receptor
by: Jeovanna Lowe, et al.
Published: (2025-12-01)

Mineralocorticoid Receptor Blocker Prevents Mineralocorticoid Receptor–Mediated Inflammation by Modulating Transcriptional Activity of Mineralocorticoid Receptor–p65–Signal Transducer and Activator of Transcription 3 Complex
by: Naoto Kuyama, et al.
Published: (2024-09-01)

Changes of myocardial fibrosis markers with the use of beta-blockers and mineralocorticoid receptor antagonists in patients with heart failure with mid-range ejection fraction of ischemic origin
by: O. A. Osipova, et al.
Published: (2021-11-01)

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice
by: Maria Alfarano, MD, PhD, et al.
Published: (2025-06-01)

Major Adverse Cardiovascular Events in Primary Aldosteronism After Adrenalectomy or Mineralocorticoid Receptor Antagonist Treatment: A Systematic Review and Meta‐Analysis
by: Chien‐Wei Huang, et al.
Published: (2025-02-01)

Recent Advances and Perspectives on the Use of Mineralocorticoid Receptor Antagonists for the Treatment of Hypertension and Chronic Kidney Disease: A Review
by: Kisho Miyasako, et al.
Published: (2024-12-01)

Vascular cell‐specific roles of mineralocorticoid receptors in pulmonary hypertension
by: Divya P. Menon, et al.
Published: (2021-07-01)

FIDELIO study: significance and place of finerenone as nonsteroidal mineralocorticoid receptor antagonist in therapy of patients with chronic kidney disease in type 2 diabetes
by: M. S. Shamkhalova, et al.
Published: (2023-12-01)

Adrenal venous sampling outcomes with and without mineralocorticoid receptor antagonists in primary aldosteronism
by: Sittikul Thipbumrung, et al.
Published: (2025-07-01)

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials
by: Paula Dibo, et al.
Published: (2025-08-01)

Treatment Patterns, Adverse Events, and Clinical Outcomes with Steroidal Mineralocorticoid Receptor Antagonists: A Retrospective Analysis of Administrative Claims Data (RELICS)
by: Richard EL, et al.
Published: (2025-02-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study [Corrigendum]
by: Fei Y, et al.
Published: (2025-06-01)

Pharmacokinetics and Safety of HRS-1780 in Renal Impaired Subjects: A Multicenter, Non-Randomized, Open-Label Study
by: Fei Y, et al.
Published: (2025-05-01)

Effects of spironolactone and eplerenone on left ventricular diastolic function and neurohumoral factors in patients with heart failure
by: N. A. Nuritdinov, et al.
Published: (2020-12-01)

PATIENT WITH CHRONIC HEART FAILURE. RATIONAL CHOICE OF THERAPY
by: O. M. Drapkina, et al.
Published: (2017-09-01)

The effectiveness of eplerenone in clinical practice from the standpoint of evidence-based medicine (twenty years on the guard of life)
by: A. G. Evdokimova, et al.
Published: (2023-01-01)

A Prospective Crossover Clinical Trial of Esaxerenone and Eplerenone in Patients with Chronic Heart Failure Complicated by Hypertension
by: Akira Sezai, et al.
Published: (2025-05-01)

Characteristic analysis of adverse reactions of finerenone: an in-depth analysis from WHO-VigiAccess
by: Hongxuan Fan, et al.
Published: (2025-08-01)

Focus on Finerenone, a Non-Steroidal MRA in Diabetic Kidney Disease. What Physicians Should Know?
by: Dwaipayan Sarathi CHAKRABORTY, et al.
Published: (2022-03-01)

Multimodality Imaging in Aldosterone-Induced Cardiomyopathy: Early Detection and Prognostic Implications
by: Francesca Zoccatelli, et al.
Published: (2025-07-01)

Efficacy and Safety of Low‐Dose Spironolactone in Management of Diabetic Kidney Disease in a Real‐World Setting
by: Manochehr Amini, et al.
Published: (2025-07-01)

Prospects of finerenone use in Russian population of patients with chronic kidney disease and type 2 diabetes. Resolution of multidisciplinary. Advisory board
by: M. V. Shestakova, et al.
Published: (2023-11-01)

Novel cardioprotective and nephroprotective combination in patients with type 2 diabetes and chronic kidney disease: perspectives of use
by: Yu. Sh. Khalimov, et al.
Published: (2024-03-01)

Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial
by: Subha V. Raman, et al.
Published: (2019-10-01)

To MRAs treatment or not? evidence from a meta-analysis of randomized controlled trials of different MRAs on cardiovascular health in heart failure
by: Jinyu He, et al.
Published: (2025-07-01)

The Effect of Early Spironolactone Administration on 2-Year Acute Graft Rejection in Cardiac Transplant Patients
by: Dragos-Florin Baba, et al.
Published: (2025-05-01)

Evidence for the use of a nonsteroidal mineralocorticoid receptor antagonist for the treatment of chronic kidney disease
by: Mariana Morais David Pliças, et al.
Published: (2025-03-01)

ALDOSTERONE AND OBESITY: WHERE TO LOOK FOR THE KEY TO THERAPY?
by: N. T. Vatutin, et al.
Published: (2016-08-01)

MINERALOCORTICOID ANTAGONISM: SELECTIVENESS GIVES MORE OPPORTUNITIES FOR HEART FAILURE MANAGEMENT
by: V. N. Soboleva, et al.
Published: (2015-01-01)

Finerenone in diabetic kidney disease: a new frontier for slowing disease progression
by: Ibrahim S. Alhomoud, et al.
Published: (2025-06-01)

Hipoadrenocorticismo em cães
by: Luiza Mendes de Souza, et al.
Published: (2024-09-01)

Chronic kidney disease in patients with type 2 diabetes: new targets of medicine action
by: N. P. Trubitsyna, et al.
Published: (2022-12-01)

Advantages of long-term combination pharmacotherapy with a beta-blocker and eplerenone in patients with ST-segment elevation acute coronary syndrome
by: O. A. Osipova, et al.
Published: (2022-07-01)

Influence of aldosterone antagonists on markers of electrophysiological instability in patients with heart failure with mid-range ejection fraction after ST-segment elevation acute coronary syndrome in the short- and long-term periods
by: L. V. Shekhovtsova, et al.
Published: (2020-11-01)

Heart rate reactivity, recovery, and endurance of the incremental shuttle walk test in patients prone to heart failure
by: Fang‐Fei Wei, et al.
Published: (2024-12-01)

Pseudohipoaldosteronismo y aparente exceso de mineralocorticoides. Cara y ceca en dos pacientes pediátricos
by: María Florencia Kuspiel, et al.
Published: (2025-03-01)